{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:26:23Z","timestamp":1793651183187,"version":"4.5.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":254,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) based on the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysis evaluated outcomes in ATTR-ACT and its long-term extension study (LTE) by baseline National Amyloidosis Centre (NAC) stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients received either the approved dose of tafamidis 80\u2009mg or placebo in ATTR-ACT and tafamidis in the LTE. All-cause and cardiovascular (CV)-related mortality, CV-related hospitalizations, and Kansas City Cardiomyopathy Questionnaire overall summary and clinical summary (KCCQ-OS\/CS) scores were assessed up to 90\u2009months of follow-up. Of 353 patients, 350 were evaluable for NAC staging. At baseline, 42%, 38%, and 20% were NAC stage I, II, and III, respectively. At the end of study, all-cause mortality was lower in the continuous tafamidis versus placebo to tafamidis groups at NAC stages I (36% vs. 61%; hazard ratio [HR] 0.43, p\u2009&amp;lt;\u20090.001) and II (55% vs. 74%; HR 0.51, p\u2009=\u20090.003); with a numerical trend at stage III (69% vs. 88%; HR 0.75, p\u2009=\u20090.298). Survival curves diverged early in patients at NAC stage I, but later at higher stages. Similar patterns were observed for CV-related mortality. Continuous tafamidis versus placebo to tafamidis groups at NAC stages I\/II had lower CV-related hospitalization rates and frequently smaller declines in KCCQ-OS\/CS scores over follow-up; with favourable trends at stage III.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I\/II ATTR-CM, with favourable trends at stage III. This illustrates the importance of early diagnosis and initiation of disease-modifying therapy.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: ClinicalTrials.gov, NCT01994889, NCT02791230.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3696","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T08:48:58Z","timestamp":1749458938000},"page":"2998-3009","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage"],"prefix":"10.1093","volume":"27","author":[{"given":"Thibaud","family":"Damy","sequence":"first","affiliation":[{"name":"Department of Cardiology, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2026061714102908000_ejhf3696-bib-0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026061714102908000_ejhf3696-bib-0002","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026061714102908000_ejhf3696-bib-0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026061714102908000_ejhf3696-bib-0004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026061714102908000_ejhf3696-bib-0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaccao.2019.11.006","article-title":"Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy","volume":"1","author":"Feng","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026061714102908000_ejhf3696-bib-0006","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026061714102908000_ejhf3696-bib-0007","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026061714102908000_ejhf3696-bib-0008","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026061714102908000_ejhf3696-bib-0009","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: Taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2026061714102908000_ejhf3696-bib-0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026061714102908000_ejhf3696-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026061714102908000_ejhf3696-bib-0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026061714102908000_ejhf3696-bib-0013","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026061714102908000_ejhf3696-bib-0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2026061714102908000_ejhf3696-bib-0015","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.997","article-title":"Survival analysis of tafamidis use in patients with ATTR cardiac amyloidosis","volume":"44","author":"Starr","year":"2023","journal-title":"Eur Heart J"},{"key":"2026061714102908000_ejhf3696-bib-0016","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/cer-2021-0071","article-title":"Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2026061714102908000_ejhf3696-bib-0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061714102908000_ejhf3696-bib-0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061714102908000_ejhf3696-bib-0019","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026061714102908000_ejhf3696-bib-0020","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0735-1097(22)01297-9","article-title":"Tafamidis effectiveness in wild-type transthyretin cardiac amyloidosis by Mayo staging","volume":"79","author":"Amaka","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026061714102908000_ejhf3696-bib-0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: Further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026061714102908000_ejhf3696-bib-0022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","article-title":"Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: An analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies","volume":"8","author":"Rozenbaum","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026061714102908000_ejhf3696-bib-0023","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"},{"key":"2026061714102908000_ejhf3696-bib-0024","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.2115","article-title":"Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy","volume":"41","author":"Rapezzi","year":"2020","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2998\/66836484\/eurjhf_27_12_2998.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2998\/66836484\/eurjhf_27_12_2998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:10:35Z","timestamp":1781719835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/12\/2998\/8470702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3696","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"2024-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}